ABSTRACT:
Diltiazem HCl is a calcium ion channel inhibitor. The ability to inhibit the influx of calcium ion present in of cardiac and vascular smooth muscle during membrane depolarization is believed to be its therapeutic effect. It is widely used in the treatment of several types of cardiovascular disorders. For achieving better drug product effectiveness, reliability and safety in the modern pharmaceutical design and intensive research, controlled release and extended release drug delivery has become standards. The largest share of drug delivery systems i.e. upto 80% of all the medication accounts to the OSRDD (Oral Sustained Release Drug Delivery). Extended releases tablets of diltiazem HCL was formulated using Hydroxypropyl methylcellulose (HPMC 643) and povidone in different ratios, the extended release behaviour of fabricated tablets were then evaluated. Extended release diltiazem HCL tablets were composed by direct compression method. Formulation was optimized on the basis of different tablet properties and drug release pattern in In-vitro release profile. The resulting formulation produced tablets with required hardness, weight uniformity and friability. The result of In-vitro dissolution study showed that formulation F4 is most appropriate formulation as it exhibits drug release pattern for much longer period of time. A decrease in drug release profile of the drug was observed on increasing polymer ratio.